BR112014013250A2 - compostos com enzima alvo e usos dos mesmos - Google Patents

compostos com enzima alvo e usos dos mesmos

Info

Publication number
BR112014013250A2
BR112014013250A2 BR112014013250A BR112014013250A BR112014013250A2 BR 112014013250 A2 BR112014013250 A2 BR 112014013250A2 BR 112014013250 A BR112014013250 A BR 112014013250A BR 112014013250 A BR112014013250 A BR 112014013250A BR 112014013250 A2 BR112014013250 A2 BR 112014013250A2
Authority
BR
Brazil
Prior art keywords
compounds
enzyme
compound
target
iduronate
Prior art date
Application number
BR112014013250A
Other languages
English (en)
Inventor
Boivin Dominique
Currie Jean-Christophe
Castaigne Jean-Paul
Demeule Michel
Tripathy Sasmita
Lord-Dufour Simon
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of BR112014013250A2 publication Critical patent/BR112014013250A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

targeted enzyme compounds and uses thereof abstract of the disclosure the present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and angiopep-2. in certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. the invention also features methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis type ii) using such compounds. ____________________________ tradução do resumo resumo patente de invenção: "compostos com enzima alvo e usos dos mesmos". a presente invenção refere-se a um composto que inclui uma enzima lisossomal e uma porção alvo, por exemplo, onde o com-posto é uma proteína de fusão incluindo iduronato-2-sulfatase e angi-opep-2. em certas modalidades, esses compostos, devido à presença da porção alvo, podem cruzar a barreira cérebro-sangue ou acumular no lisossoma mais eficazmente do que a enzima sozinha. a invenção refere-se também a métodos para tratamento de distúrbios de arma-zenamento lisossomal (por exemplo, mucopolissacaridose tipo ii) u-sando tais compostos.
BR112014013250A 2011-12-01 2012-11-30 compostos com enzima alvo e usos dos mesmos BR112014013250A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161565764P 2011-12-01 2011-12-01
US201261596516P 2012-02-08 2012-02-08
PCT/CA2012/050865 WO2013078562A2 (en) 2011-12-01 2012-11-30 Targeted enzyme compounds and uses thereof

Publications (1)

Publication Number Publication Date
BR112014013250A2 true BR112014013250A2 (pt) 2019-09-24

Family

ID=48536182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013250A BR112014013250A2 (pt) 2011-12-01 2012-11-30 compostos com enzima alvo e usos dos mesmos

Country Status (10)

Country Link
US (1) US20140335163A1 (pt)
EP (1) EP2785837A4 (pt)
JP (1) JP2015500800A (pt)
CN (1) CN104136606A (pt)
AU (1) AU2012344700A1 (pt)
BR (1) BR112014013250A2 (pt)
CA (1) CA2857548A1 (pt)
HK (1) HK1200190A1 (pt)
RU (1) RU2014126482A (pt)
WO (1) WO2013078562A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583562T3 (da) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
ES2424242T3 (es) 2005-07-15 2013-09-30 Angiochem Inc. Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
MX2011006685A (es) 2008-12-17 2011-09-27 Angiochem Inc Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
IN2012DN00248A (pt) 2009-07-02 2015-05-01 Angiochem Inc
AU2012344702A1 (en) * 2011-12-01 2014-06-19 Angiochem Inc. Targeted lysosomal enzyme compounds
WO2013181697A1 (en) * 2012-06-05 2013-12-12 The University Of Melbourne Bicyclo[6.1.0]non-4-yne compounds suitable for use as linkers in biological applications
WO2013185235A1 (en) * 2012-06-15 2013-12-19 Angiochem Inc. Targeted iduronidase compounds
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF
WO2014082184A1 (en) * 2012-11-30 2014-06-05 Angiochem Inc. Targeted iduronate-2-sulfatase compounds
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
WO2014194427A1 (en) * 2013-06-06 2014-12-11 Angiochem Inc. Targeted iduronate-2-sulfatase fusion proteins
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
KR102368068B1 (ko) 2015-08-24 2022-02-25 삼성전자주식회사 반도체 소자 제조용 조성물 및 이를 이용하는 반도체 소자의 제조 방법
GB201603296D0 (en) 2016-02-25 2016-04-13 Ucl Business Plc Chemotactic,drug-containing polymersomes
GB201604553D0 (en) 2016-03-17 2016-05-04 Ucl Business Plc Fumarate polymersomes
JP6993814B2 (ja) * 2016-08-25 2022-01-14 Ｊｃｒファーマ株式会社 抗体融合蛋白質の製造方法
GB201701968D0 (en) 2017-02-07 2017-03-22 Univ Manchester Gene therapy
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020144467A1 (en) 2019-01-07 2020-07-16 Ucl Business Ltd Polymersomes functionalised with multiple ligands
CA3238273A1 (en) 2021-11-24 2023-06-01 Giuseppe Battaglia Polymersomes for clearance of amyloid beta and/or tau proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487815A1 (en) * 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
WO2004108071A2 (en) * 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
WO2006108052A2 (en) * 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
CN101946001A (zh) * 2007-12-20 2011-01-12 安吉奥开米公司 多肽-核酸结合物及其应用
US9914754B2 (en) * 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
JP2013506697A (ja) * 2009-10-06 2013-02-28 アンジオケム インコーポレーテッド 治療薬を輸送するための組成物と方法
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases

Also Published As

Publication number Publication date
EP2785837A2 (en) 2014-10-08
EP2785837A4 (en) 2015-07-01
CA2857548A1 (en) 2013-06-06
WO2013078562A2 (en) 2013-06-06
HK1200190A1 (en) 2015-07-31
WO2013078562A3 (en) 2013-09-06
US20140335163A1 (en) 2014-11-13
RU2014126482A (ru) 2016-01-27
AU2012344700A1 (en) 2014-06-19
CN104136606A (zh) 2014-11-05
JP2015500800A (ja) 2015-01-08

Similar Documents

Publication Publication Date Title
BR112014013250A2 (pt) compostos com enzima alvo e usos dos mesmos
BR112014013161A2 (pt) compostos com enzima lisossomal alvo
BR112014031273A2 (pt) compostos enzima alvejados e seus usos
BR112014027227A2 (pt) modificação alvejada de malato desidrogenase
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
BR112012011072A2 (pt) inibidores de n1-pirazolospirocetona acetil-coa carboxilase
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112014016163A2 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
BR112015012197A2 (pt) terapia de combinação
BR112013030894A2 (pt) moduladores do sistema imune
BRPI0615690B8 (pt) compostos heterocíclicos de hidroxamato, seus usos e composição farmacêutica
BR112021019880A2 (pt) Terapias gênicas para distúrbios lisossomais
BR112012029634A2 (pt) agentes herbicidas para as culturas de arroz tolerantes ou resistentes
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
BR112015007083A2 (pt) inibidores de histona demetilases
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
BR112014013963A8 (pt) compostos inibidores de metaloenzimas
BR112014003109A2 (pt) variantes de plasminogênio e plasmina
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112015006305A2 (pt) composições farmacêuticas para prevenir e/ou tratar dislipidemia e para aumentar o colesterol de hdl
BR112012027143A2 (pt) enzima da doença do armazenamento lisossomal

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.